Safety of Intravenous Immunoglobulin (Tegeline (R)), Administered at Home in Patients with Autoimmune Disease: Results of a French Study - Université de Lille
Article Dans Une Revue BioMed Research International Année : 2018

Safety of Intravenous Immunoglobulin (Tegeline (R)), Administered at Home in Patients with Autoimmune Disease: Results of a French Study

Gwendal Le Masson
  • Fonction : Auteur
Guilhem Sole
  • Fonction : Auteur
Mohamed Hamidou
  • Fonction : Auteur
Claude Desnuelle
  • Fonction : Auteur
Jean-Philippe Azulay
  • Fonction : Auteur
Gerard Besson
  • Fonction : Auteur
Laure Swiader
  • Fonction : Auteur
Sebastien Abad
  • Fonction : Auteur
Jean-Christophe Antoine
Francoise Bouhour
  • Fonction : Auteur
Alain Creange
  • Fonction : Auteur
Marike Grenouillet
  • Fonction : Auteur
Laurent Magy
  • Fonction : Auteur
Sebastien Marcel
  • Fonction : Auteur
Jean-Michel Paquet
  • Fonction : Auteur
Francois Rouhart
  • Fonction : Auteur
Francois Ziegler
  • Fonction : Auteur
Stephane Mathis
  • Fonction : Auteur
Marc Gauthier-Darnis
  • Fonction : Auteur
Sophie Puget
  • Fonction : Auteur

Résumé

The efficacy of intravenous immunoglobulins (IVIg) in patients with autoimmune diseases (AID) has been known for several decades. Majority of these patients received IVIg in hospital. A retrospective study was conducted in 22 centers in France to evaluate the feasibility of the administration of Tegeline, an IVIg from LFB Biomedicaments, and assess its safety at home, compared to in hospital, in patients with AID. The included patients were at least 18 years old, suffering from AID, and treated with at least 1 cycle of Tegeline at home after receiving 3 consecutive cycles of hospital-based treatment with Tegeline at a dose between 1 and 2 g/kg/cycle. Forty-six patients with AID, in most cases immune-mediated neuropathies, received a total of 138 cycles of Tegeline in hospital and then 323 at home. Forty-five drug-related adverse events occurred in 17 patients who received their cycles at home compared to 24 adverse events in hospital in 15 patients. Serious adverse events occurred in 3 patients during home treatment, but they were not life-threatening and did not lead to discontinuation of Tegeline. Forty-five patients continued their treatment with Tegeline at home or in hospital; 39 (84.8%) were still receiving home treatment at the end of the study. In conclusion, the study demonstrates the good safety profile of Tegeline administered at home at high doses in patients with AID who are eligible for home administration of Tegeline.
Fichier principal
Vignette du fichier
8147251.pdf (1.33 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04417290 , version 1 (25-01-2024)

Licence

Identifiants

Citer

Eric Hachulla, Gwendal Le Masson, Guilhem Sole, Mohamed Hamidou, Claude Desnuelle, et al.. Safety of Intravenous Immunoglobulin (Tegeline (R)), Administered at Home in Patients with Autoimmune Disease: Results of a French Study. BioMed Research International , 2018, BioMed Research International, 2018, ⟨10.1155/2018/8147251⟩. ⟨hal-04417290⟩

Collections

RIIP UNIV-LILLE
12 Consultations
4 Téléchargements

Altmetric

Partager

More